Latest News

New RCT finds ketogenic diet cuts liver fat and improves glycemic control more than Mediterranean or plant-forward diets after matched weight loss.

Chronic spontaneous urticaria treatment now spans 3 systemic options after a major international guideline update.

The investigational therapy did not achieve statistical significance in KCCQ-TSS or in 6MWD, but saw substantial changes in exploratory secondary endpoints.

H-ISDN missed its primary endpoint in H-HeFT, but a pooled meta-analysis found significant reductions in all-cause and cardiovascular death in HFrEF.

The China Rural Hypertension Control Program found a non-physician-led intensive blood pressure intervention reduced dementia risk by 15% over 7 years.

EPIDAURUS stopped early after potent P2Y12 inhibitors plus a DOAC raised bleeding without reducing ischemic events in patients with AF and MI.

ACASA-TAVI found NOAC monotherapy cut subclinical leaflet thrombosis nearly in half versus aspirin after TAVI, meeting safety noninferiority.

CMR GUIDE found ICD implantation did not significantly reduce sudden cardiac death or dangerous arrhythmia versus a loop recorder in LVEF 36-50%.

Phase 2b LUMINARA results showed the oral relaxin agonist AZD5462 improved echocardiographic measures of cardiac function in patients with chronic heart failure.

A roundup of the top cardiology news out of ESC Congress2026 on day 2, spanning primary prevention, novel therapies, and antibiotic stewardship.

New MILOS data show bempedoic acid-based therapy translated to meaningful reductions in predicted 10-year cardiovascular risk.

The REACT study found silent atherosclerosis in 57.1% of adults without known cardiovascular disease, a burden largely missed by the SCORE2 risk tool.

A longitudinal survey found PSVT disrupts patients' daily activities, sleep, and emotions between episodes.

Despite failing to display a clinically significant reduction in all-cause death or hospitalization for cardiovascular events, the trial did highlight evolocumab’s LDL-C-lowering capacity.

CTX310, a CRISPR-Cas9 therapy targeting ANGPTL3, sustained deep LDL and triglyceride reductions at 1 year after a single infusion, per ESC 2026 data.

POET-II found tailored antibiotics cut treatment duration by a third in left-sided infective endocarditis without compromising safety, per ESC 2026 data.

PREMIUM found prasugrel monotherapy before primary PCI raised ischemic risk vs DAPT in STEMI despite less major bleeding, per ESC Congress 2026 data.

The phase 2 TRANQUILITY trial found the IL-6 antibody pacibekitug produced sustained, dose-dependent reductions in hs-CRP in patients with chronic kidney disease.

Milvexian added to standard antiplatelet therapy did not lower MACE or increase intracranial/fatal bleeding versus placebo after ACS.

The ENRICH-AF trial found edoxaban did not significantly reduce stroke or systemic embolism but increased major bleeding in patients with AF and prior intracranial hemorrhage.

STAREE findings show atorvastatin reduced major cardiovascular events by 30% in older adults without known cardiovascular disease, but disability-free survival was unchanged.

Karolinska Institute's Johannes Blom, MD, PhD, explains why colorectal cancer screening's real-world mortality benefit has been underestimated.

A roundup of the biggest cardiology news out of ESC Congress on day 1, spanning new guidelines, a phase 3 miss, and 2 practice-informing trial readouts.